Serina Therapeutics (SER) Operating Leases (2019 - 2026)

Serina Therapeutics has disclosed Operating Leases across 6 years of filings, most recently posting $122000.0 for Q2 2026.

• In Q2 2026, Operating Leases fell 66.3% year-over-year to $122000.0; the TTM figure through Jun 2026 stood at $122000.0 (down 66.3% YoY), while the FY2025 annual figure was $196000.0, down 26.87% from the prior year.
• Operating Leases came in at $122000.0 for Q2 2026 at Serina Therapeutics, down from $196000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $675000.0 in Q4 2023 to a low of $122000.0 in Q2 2026.
• Average Operating Leases over 4 years is $363000.0, with a median of $362000.0 recorded in 2024.
• Year-over-year, Operating Leases changed 0.0% in 2025 and sank 66.3% in 2026.
• Over 4 years, Operating Leases stood at $675000.0 in 2023, then slumped by 60.3% to $268000.0 in 2024, then fell by 26.87% to $196000.0 in 2025, then slumped by 37.76% to $122000.0 in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $122000.0 in Q2 2026, $196000.0 in Q4 2025, and $311000.0 in Q3 2025.